SG Americas Securities LLC Buys Shares of 9,740 Cabaletta Bio, Inc. (NASDAQ:CABA)

SG Americas Securities LLC acquired a new position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 9,740 shares of the company’s stock, valued at approximately $221,000.

Several other institutional investors also recently modified their holdings of CABA. Vanguard Group Inc. lifted its position in shares of Cabaletta Bio by 14.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,968,108 shares of the company’s stock worth $29,955,000 after buying an additional 246,596 shares during the period. Citigroup Inc. raised its position in Cabaletta Bio by 552.4% in the 3rd quarter. Citigroup Inc. now owns 49,695 shares of the company’s stock valued at $756,000 after purchasing an additional 42,078 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Cabaletta Bio in the 3rd quarter valued at $3,753,000. Deutsche Bank AG increased its stake in shares of Cabaletta Bio by 84.7% in the 3rd quarter. Deutsche Bank AG now owns 21,135 shares of the company’s stock valued at $322,000 after buying an additional 9,692 shares during the period. Finally, Comerica Bank acquired a new stake in shares of Cabaletta Bio in the 3rd quarter valued at $31,000.

Cabaletta Bio Trading Up 0.3 %

Cabaletta Bio stock opened at $17.91 on Friday. Cabaletta Bio, Inc. has a 12 month low of $7.69 and a 12 month high of $26.35. The stock’s 50 day moving average is $20.59 and its 200-day moving average is $18.91. The company has a market capitalization of $864.01 million, a price-to-earnings ratio of -10.85 and a beta of 2.41.

Insider Activity

In related news, insider Gwendolyn Binder sold 11,000 shares of the stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $19.59, for a total transaction of $215,490.00. Following the sale, the insider now owns 20,000 shares of the company’s stock, valued at $391,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on CABA shares. Jefferies Financial Group started coverage on Cabaletta Bio in a research note on Monday, February 5th. They set a “buy” rating and a $36.00 price objective for the company. HC Wainwright boosted their target price on Cabaletta Bio from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. Citigroup boosted their price target on Cabaletta Bio from $26.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Wells Fargo & Company upped their target price on Cabaletta Bio from $34.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 target price on shares of Cabaletta Bio in a report on Friday, April 5th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $34.33.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.